

Claus RÃ¶del

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11458176/publications.pdf>

Version: 2024-02-01

181
papers

21,500
citations

22153

59
h-index

9345

143
g-index

210
all docs

210
docs citations

210
times ranked

14683
citing authors

#	ARTICLE	IF	CITATIONS
1	Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1731-1740.	27.0	5,296
2	Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. <i>Journal of Clinical Oncology</i> , 2012, 30, 1926-1933.	1.6	1,673
3	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2010, 11, 835-844.	10.7	1,532
4	Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 8688-8696.	1.6	1,102
5	Combined-Modality Treatment and Selective Organ Preservation in Invasive Bladder Cancer: Long-Term Results. <i>Journal of Clinical Oncology</i> , 2002, 20, 3061-3071.	1.6	602
6	Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 679-687.	10.7	585
7	Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 979-989.	10.7	577
8	Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2011, 29, 3163-3172.	1.6	439
9	Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 99-107.	0.8	396
10	Tumor Regression Grading After Preoperative Chemoradiotherapy for Locally Advanced Rectal Carcinoma Revisited: Updated Results of the CAO/ARO/AIO-94 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1554-1562.	1.6	351
11	EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014, 50, 1.e1-1.e34.	2.8	349
12	Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. <i>Journal of Clinical Oncology</i> , 2019, 37, 3212-3222.	1.6	333
13	Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 3098-3104.	1.6	277
14	Survivin as a Radioresistance Factor, and Prognostic and Therapeutic Target for Radiotherapy in Rectal Cancer. <i>Cancer Research</i> , 2005, 65, 4881-4887.	0.9	248
15	Multicenter Phase II Trial of Chemoradiation With Oxaliplatin for Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2007, 26, 110-117.	1.6	204
16	What is the role of radiotherapy in bladder-preserving cancer therapy?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 4-5.	4.3	193
17	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	5.1	184
18	The abdominoperineal resection itself is associated with an adverse outcome: The European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. <i>European Journal of Cancer</i> , 2009, 45, 1175-1183.	2.8	171

#	ARTICLE	IF	CITATIONS
19	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	3.3	163
20	Trimodality Treatment and Selective Organ Preservation for Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 5536-5544.	1.6	151
21	Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: Survivin as a radioresistance factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1341-1347.	0.8	146
22	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.6	141
23	Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1081-1086.	0.8	138
24	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.6	130
25	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	7.0	127
26	Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2022, 8, e215445.	7.1	127
27	Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 294-303.	0.8	119
28	Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer. <i>Cancer Cell</i> , 2022, 40, 168-184.e13.	16.8	117
29	Nuclear export is essential for the tumor-promoting activity of survivin. <i>FASEB Journal</i> , 2007, 21, 207-216.	0.5	116
30	Adjuvant versus Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer A Progress Report of a Phase-III Randomized Trial (Protocol CAO/ARO/AIO-94). <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 173-181.	2.0	115
31	Radiochemotherapy After Transurethral Resection for High-Risk T1 Bladder Cancer: An Alternative to Intravesical Therapy or Early Cystectomy?. <i>Journal of Clinical Oncology</i> , 2006, 24, 2318-2324.	1.6	105
32	Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	105
33	Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 1213-1221.	0.8	104
34	Immunomodulatory Properties and Molecular Effects in Inflammatory Diseases of Low-Dose X-Irradiation. <i>Frontiers in Oncology</i> , 2012, 2, 120.	2.8	97
35	Survivin Antisense Oligonucleotides Effectively Radiosensitize Colorectal Cancer Cells in Both Tissue Culture and Murine Xenograft Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 247-255.	0.8	96
36	High Survivin Expression is Associated with Reduced Apoptosis in Rectal Cancer and May Predict Disease-Free Survival after Preoperative Radiochemotherapy and Surgical Resection. <i>Strahlentherapie Und Onkologie</i> , 2002, 178, 426-435.	2.0	94

#	ARTICLE	IF	CITATIONS
37	Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. <i>International Journal of Cancer</i> , 2015, 137, 212-220.	5.1	94
38	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
39	Evidence and research in rectal cancer. <i>Radiotherapy and Oncology</i> , 2008, 87, 449-474.	0.6	92
40	Expression of TIP60 (tata€interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. <i>BJU International</i> , 2012, 110, E1228-36.	2.5	92
41	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	5.1	91
42	Radiochemotherapy With Cisplatin and 5-Fluorouracil After Transurethral Surgery in Patients With Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1072-1080.	0.8	88
43	Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 227-235.	2.0	87
44	Heat Shock Protein 70 (Hsp70) Peptide Activated Natural Killer (NK) Cells for the Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) after Radiochemotherapy (RCTx) – From Preclinical Studies to a Clinical Phase II Trial. <i>Frontiers in Immunology</i> , 2015, 6, 162.	4.8	87
45	Human papilloma virus load and PD-1/PD-L1, CD8⁺ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1288331.	4.6	79
46	Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. <i>Radiotherapy and Oncology</i> , 2010, 97, 382-386.	0.6	77
47	Association of Plane of Total Mesorectal Excision With Prognosis of Rectal Cancer. <i>JAMA Surgery</i> , 2018, 153, e181607.	4.3	77
48	EURECCA colorectal: Multidisciplinary Mission statement on better care for patients with colon and rectal cancer in Europe. <i>European Journal of Cancer</i> , 2013, 49, 2784-2790.	2.8	76
49	Human papillomavirus DNA load and p16^{INK4a} expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>International Journal of Cancer</i> , 2015, 136, 278-288.	5.1	75
50	15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment. <i>Anticancer Research</i> , 2011, 31, 985-90.	1.1	75
51	The Role of Survivin for Radiation Therapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 593-599.	2.0	74
52	Concurrent Chemoradiotherapy With 5-Fluorouracil and Mitomycin C for Invasive Anal Carcinoma in Human Immunodeficiency Virus-Positive Patients Receiving Highly Active Antiretroviral Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1425-1432.	0.8	72
53	Preoperative Radiation with Concurrent 5-Fluorouracil for Locally Advanced T4-Primary Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2000, 176, 161-167.	2.0	70
54	Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma. <i>Radiotherapy and Oncology</i> , 2011, 101, 51-58.	0.6	70

#	ARTICLE	IF	CITATIONS
55	Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1008-1019.	0.8	69
56	Radiotherapy for Bladder Cancer. Urology, 2007, 69, 80-92.	1.0	68
57	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. Clinical Cancer Research, 2019, 25, 1505-1516.	7.0	67
58	Frequency of HER-2 Positivity in Rectal Cancer and Prognosis. American Journal of Surgical Pathology, 2013, 37, 522-531.	3.7	64
59	Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: Are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy?. Radiotherapy and Oncology, 2011, 98, 99-104.	0.6	62
60	Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer. Oncoimmunology, 2014, 3, e27403.	4.6	61
61	EURECCA consensus conference highlights about rectal cancer clinical management: The radiation oncologist's expert review. Radiotherapy and Oncology, 2014, 110, 195-198.	0.6	61
62	Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer. American Journal of Pathology, 2010, 177, 918-929.	3.8	58
63	Radiation Therapy for Early Stages of Morbus Ledderhose. Strahlentherapie Und Onkologie, 2010, 186, 24-29.	2.0	56
64	Outcome measures in multimodal rectal cancer trials. Lancet Oncology, The, 2020, 21, e252-e264.	10.7	56
65	Study of the anti-inflammatory effects of low-dose radiation. Strahlentherapie Und Onkologie, 2015, 191, 742-749.	2.0	55
66	Preoperative Radiotherapy of Advanced Rectal Cancer With Capecitabine and Oxaliplatin With or Without Cetuximab: A Pooled Analysis of Three Prospective Phase I-II Trials. International Journal of Radiation Oncology Biology Physics, 2010, 78, 472-478.	0.8	53
67	Radiation-Induced Survivin Nuclear Accumulation is Linked to DNA Damage Repair. International Journal of Radiation Oncology Biology Physics, 2010, 77, 226-234.	0.8	53
68	Radiotherapy and "new" drugs-new side effects?. Radiation Oncology, 2011, 6, 177.	2.7	53
69	Regional lymph node metastasis and locoregional recurrence of rectal carcinoma in the era of TNM surgery. Implications for treatment decisions. International Journal of Colorectal Disease, 2010, 25, 359-368.	2.2	51
70	Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer. Clinical Cancer Research, 2011, 17, 3469-3477.	7.0	51
71	Bladder preservation in muscle-invasive bladder cancer by conservative surgery and radiochemotherapy. Journal of Surgical Oncology, 2001, 20, 24-32.	1.4	50
72	Molecular targeted treatment and radiation therapy for rectal cancer. Strahlentherapie Und Onkologie, 2009, 185, 371-378.	2.0	50

#	ARTICLE	IF	CITATIONS
73	Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	5.1	50
74	Management of Superficial Recurrences in an Irradiated Bladder After Combined-Modality Organ-Preserving Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1502-1506.	0.8	49
75	Targeting by cmHsp70.1-antibody coated and survivin miRNA plasmid loaded nanoparticles to radiosensitize glioblastoma cells. <i>Journal of Controlled Release</i> , 2013, 172, 201-206.	9.9	49
76	Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 302-309.	0.6	49
77	Rectal cancer: Neoadjuvant chemoradiotherapy. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 629-639.	2.4	49
78	A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. <i>Radiotherapy and Oncology</i> , 2012, 103, 394-401.	0.6	46
79	Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival. <i>Cancer</i> , 2013, 119, 26-35.	4.1	46
80	The role of recent nanotechnology in enhancing the efficacy of radiation therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 130-143.	7.4	46
81	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	7.0	45
82	Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF- κ B activation and mediates the anti-inflammatory properties of low-dose ionising-radiation. <i>Radiotherapy and Oncology</i> , 2010, 97, 346-351.	0.6	44
83	Organ Preservation in Rectal Cancer: The Patients' Perspective. <i>Frontiers in Oncology</i> , 2019, 9, 318.	2.8	44
84	Organ preservation in patients with invasive bladder cancer: initial results of an intensified protocol of transurethral surgery and radiation therapy plus concurrent cisplatin and 5-fluorouracil. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1303-1309.	0.8	43
85	EGF61 Polymorphism Predicts Complete Pathologic Response to Cetuximab-Based Chemoradiation Independent of KRAS Status in Locally Advanced Rectal Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5161-5169.	7.0	42
86	Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. <i>Clinical Cancer Research</i> , 2020, 26, 5368-5379.	7.0	42
87	Differences Between Clinical Trial Participants and Patients in a Population-Based Registry. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 425-437.	1.3	37
88	Failure of Downregulation of Survivin Following Neoadjuvant Radiochemotherapy in Rectal Cancer Is Associated with Distant Metastases and Shortened Survival. <i>Clinical Cancer Research</i> , 2011, 17, 1623-1631.	7.0	37
89	Anal squamous cell carcinoma – State of the art management and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 65, 11-21.	7.7	37
90	Organ preservation by combined modality treatment in bladder cancer: The European perspective. <i>Seminars in Radiation Oncology</i> , 2005, 15, 28-35.	2.2	36

#	ARTICLE	IF	CITATIONS
91	Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. <i>Radiation Oncology</i> , 2013, 8, 90.	2.7	36
92	Rectal cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 441-447.	2.4	35
93	Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8. <i>Cell Research</i> , 2016, 26, 914-934.	12.0	35
94	A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. <i>Oncotarget</i> , 2016, 7, 45764-45775.	1.8	35
95	Molecular Signature for Lymphatic Metastasis in Colorectal Carcinomas. <i>Annals of Surgery</i> , 2008, 247, 803-810.	4.2	32
96	Survivin Expression as a Predictive Marker for Local Control in Patients With High-Risk T1 Bladder Cancer Treated With Transurethral Resection and Radiochemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1455-1460.	0.8	30
97	Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1283-1289.	3.7	30
98	Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. <i>Radiotherapy and Oncology</i> , 2013, 108, 32-39.	0.6	29
99	Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1225.	4.8	29
100	Induction Chemotherapy before Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 658-664.	2.0	28
101	Current Status of Radiation Therapy and Combined-Modality Treatment for Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 701-709.	2.0	27
102	Colorectal Carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 2009, 106, 843-8.	0.9	27
103	The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. <i>Radiation Oncology</i> , 2015, 10, 198.	2.7	27
104	Activator protein 1 shows a biphasic induction and transcriptional activity after low dose X-irradiation in EA.hy.926 endothelial cells. <i>Autoimmunity</i> , 2009, 42, 343-345.	2.6	26
105	Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. <i>World Journal of Urology</i> , 2013, 31, 1023-1028.	2.2	26
106	Basics of Radiation Biology When Treating Hyperproliferative Benign Diseases. <i>Frontiers in Immunology</i> , 2017, 8, 519.	4.8	26
107	Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: Long-term results of the German CAO/ARO/AIO-94 phase III trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 48-54.	0.6	25
108	Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2485.	4.1	25

#	ARTICLE	IF	CITATIONS
109	Combined-Modality Treatment and Organ Preservation in Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 213-222.	2.0	24
110	Combined-Modality Treatment for Anal Cancer. <i>Strahlentherapie Und Onkologie</i> , 2010, 186, 361-366.	2.0	24
111	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.6	24
112	Characterization of the tumor immune microenvironment and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas. <i>Oncolimmunology</i> , 2019, 8, 1614858.	4.6	24
113	Radiotherapy is an Effective Treatment for High-Risk T1-Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2001, 177, 82-88.	2.0	23
114	Neoadjuvant Short- or Long-Term Radio(chemo)therapy for Rectal Cancer: How and Who Should Be Treated?. <i>Digestive Diseases</i> , 2012, 30, 102-108.	1.9	23
115	Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon?. <i>Cancer</i> , 2015, 121, 1724-1727.	4.1	23
116	Stage-Dependent Frequency of Lymph Node Metastases in Patients With Rectal Carcinoma After Preoperative Chemoradiation: Results from the CAO/ARO/AIO-94 Trial and From a Comparative Prospective Evaluation With Extensive Pathological Workup. <i>Diseases of the Colon and Rectum</i> , 2016, 59, 377-385.	1.3	23
117	The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 221-230.	7.4	23
118	Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells. <i>Journal of Microencapsulation</i> , 2012, 29, 685-694.	2.8	21
119	A non-linear detection of phospho-histone H2AX in EA.hy926 endothelial cells following low-dose X-irradiation is modulated by reactive oxygen species. <i>Radiation Oncology</i> , 2014, 9, 80.	2.7	21
120	Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. <i>International Journal of Cancer</i> , 2019, 145, 2282-2291.	5.1	21
121	Perioperative radiotherapy and concurrent radiochemotherapy in rectal cancer. <i>Journal of Surgical Oncology</i> , 2001, 20, 3-12.	1.4	19
122	Preoperative Chemoradiation Therapy With Capecitabine/Oxaliplatin and Cetuximab in Rectal Cancer: Long-Term Results of a Prospective Phase 1/2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 992-999.	0.8	19
123	C-Reactive Protein-to-Albumin Ratio as Prognostic Marker for Anal Squamous Cell Carcinoma Treated With Chemoradiotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1200.	2.8	19
124	Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer – study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). <i>BMC Cancer</i> , 2020, 20, 8.	2.6	19
125	Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1416.	7.1	19
126	Combined Effect of Tumor Necrosis Factor-alpha and Ionizing Radiation on the Induction of Apoptosis in 5637 Bladder Carcinoma Cells. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 467-472.	2.0	18

#	ARTICLE	IF	CITATIONS
127	Organ-Sparing Multimodality Treatment for Muscle-Invasive Bladder Cancer: Can We Continue to Ignore the Evidence?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3787-3788.	1.6	18
128	Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 20.	2.8	18
129	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.6	17
130	Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer—A Promising Signaling Network for Therapeutic Interventions. <i>Cancers</i> , 2021, 13, 624.	3.7	17
131	Radiotherapy and concurrent radiochemotherapy for rectal cancer. <i>Surgical Oncology</i> , 2004, 13, 93-101.	1.6	16
132	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	1.7	16
133	Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer. <i>Oral Oncology</i> , 2020, 111, 104931.	1.5	16
134	RADIANCE — Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 43-49.	1.7	16
135	Caveolin-1 as a Prognostic Marker for Local Control After Preoperative Chemoradiation Therapy in Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 846-852.	0.8	15
136	Neoadjuvant Radiotherapy and Radiochemotherapy for Rectal Cancer. , 2005, 165, 221-230.		14
137	Preoperative chemoradiotherapy for rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 129-130.	27.6	14
138	High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. <i>Radiation Oncology</i> , 2012, 7, 88.	2.7	13
139	Modulation of radiation sensitivity and antitumor immunity by viral pathogenic factors: Implications for radio-immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 126-137.	7.4	12
140	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.6	12
141	Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 294.	7.1	12
142	Polo-like kinase 3 and phosphoT273 caspase-8 are associated with improved local tumor control and survival in patients with anal carcinoma treated with concomitant chemoradiotherapy. <i>Oncotarget</i> , 2016, 7, 53339-53349.	1.8	12
143	P27 does not predict histopathological response to radiochemotherapy in rectal cancer. <i>Journal of Surgical Research</i> , 2003, 113, 179-188.	1.6	11
144	Pretreatment Proliferation and Local Control in Bladder Cancer after Radiotherapy with or without Concurrent Chemotherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 552-556.	2.0	10

#	ARTICLE	IF	CITATIONS
145	Treatment Options for High-Risk T1 Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 443-449.	2.0	10
146	Short-Course Radiation Versus Long-Course Chemoradiation for Rectal Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1223-1231.	4.9	10
147	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	2.8	10
148	Advances in nanotechnology-based platforms for survivin-targeted drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 733-754.	5.0	10
149	A Spatial and Functional Interaction of a Heterotetramer Survivin-DNA-PKcs Complex in DNA Damage Response. <i>Cancer Research</i> , 2021, 81, 2304-2317.	0.9	8
150	Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial. <i>Radiotherapy and Oncology</i> , 2021, 164, 223-231.	0.6	8
151	Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters. <i>Strahlentherapie Und Onkologie</i> , 2017, 193, 305-314.	2.0	7
152	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 214-221.	0.6	7
153	Can clinicopathological parameters predict for lymph node metastases in ypT0-2 rectal carcinoma? Results of the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 phase 3 trials. <i>Radiotherapy and Oncology</i> , 2018, 128, 557-563.	0.6	7
154	ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 99-106.	1.7	7
155	Chemoradiation superior in muscle-invasive bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 374-375.	27.6	6
156	Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial. <i>European Journal of Cancer</i> , 2021, 144, 281-290.	2.8	6
157	Combined Systemic Therapy and Radiotherapy for Bladder Cancer. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 29-31.	2.0	5
158	Targeted agents in GI radiotherapy: Clinical efficacy and side effects. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 537-549.	2.4	5
159	Cost analysis of a wait-and-see strategy after radiochemotherapy in distal rectal cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 985-990.	2.0	5
160	Association of Polo-Like Kinase 3 and PhosphoT273 Caspase 8 Levels With Disease-Related Outcomes Among Cervical Squamous Cell Carcinoma Patients Treated With Chemoradiation and Brachytherapy. <i>Frontiers in Oncology</i> , 2019, 9, 742.	2.8	5
161	Fractionation-Dependent Radiosensitization by Molecular Targeting of Nek1. <i>Cells</i> , 2020, 9, 1235.	4.1	5
162	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.6	5

#	ARTICLE	IF	CITATIONS
163	Preoperative therapy for rectal cancer: Short-course radiation vs. long-course chemoradiation. <i>Seminars in Colon and Rectal Surgery</i> , 2014, 25, 19-21.	0.3	4
164	The Diagnosis and Treatment of Patients with Bladder Carcinoma. <i>Deutsches Arzteblatt International</i> , 2020, 118, .	0.9	4
165	Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial. <i>Frontiers in Oncology</i> , 2022, 12, 817692.	2.8	4
166	Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. <i>Physics and Imaging in Radiation Oncology</i> , 2022, 22, 1-7.	2.9	4
167	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.6	4
168	Are We There Yet? The Value of Deep Learning in a Multicenter Setting for Response Prediction of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiotherapy. <i>Diagnostics</i> , 2022, 12, 1601.	2.6	3
169	Neoadjuvant Radiochemotherapy in Rectal Cancer: For Which Patients and Tumor Stages?. , 2004, 38, 13-23.		2
170	The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94. <i>Surgical Oncology</i> , 2020, 35, 200-205.	1.6	2
171	Harnblasenkarzinom. , 2009, , 395-476.		1
172	Alternatives to surgery after failure of instillation therapy. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 307-308.	27.6	1
173	What Prognostic Clinical Factors Must Be Considered Before Treatment?. , 2012, , 21-26.		1
174	Reply to A. Abdalla et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 3562-3563.	1.6	1
175	Radiation Therapy: Adjuvant vs. Neoadjuvant Therapy. , 2010, , 223-234.		0
176	Complete response after chemoradiotherapy for rectal cancer: what is the reasonable approach?. <i>Innovative Surgical Sciences</i> , 2017, 3, 47-53.	0.7	0
177	When Should Preoperative Radiochemotherapy Be Performed?. , 2018, , 159-163.		0
178	Radiation Therapy in Rectal Cancer. , 2018, , 1-21.		0
179	Emerging Treatment Paradigms in Localized Rectal Cancer. <i>Practical Radiation Oncology</i> , 2021, 11, 26-29.	2.1	0
180	Radiation Therapy in Bladder Cancer. , 2018, , 1-12.		0

#	ARTICLE	IF	CITATIONS
181	Do We Have Enough Evidence to Propose a Preferred Total Neoadjuvant Therapy Sequence for Patients With Locally Advanced Rectal Cancer?â€”Reply. JAMA Oncology, 2022, , .	7.1	0